Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis

Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis

Abstract Aims This systematic review and meta-analysis aimed to compare the overall and site-specific cancer risk associated with SGLT2i versus DPP4i in patients with type 2 diabetes mellitus. Methods We systematically searched PubMed, Scopus, and Web of Science for cohort studies comparing cancer i...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hamed Hajishah, Parsa Mazloom, Amirhossein Salehi, Danial Kazemi, Reza Samiee, Hossein Majlesi, Mohammad Javad Amini, Arefeh Meyari, Negin Safari Dehnavi, Masood Zangi
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Series:	Diabetology & Metabolic Syndrome
Subjects:	Sodium-Glucose transporter 2 inhibitors Dipeptidyl-Peptidase IV inhibitors Diabetes mellitus, type 2 Neoplasms
Online Access:	https://doi.org/10.1186/s13098-025-01898-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)

Cardiovascular Events and Heart Failure in Patients With Type 2 Diabetes Treated With Dipeptidyl Peptidase-4 Inhibitors: A Meta-Analysis
by: Adili Tuersun, PhD, et al.
Published: (2025-01-01)

Role of DPP-4 and NPY Family Peptides in Gastrointestinal Symptoms Associated with Obesity and Type 2 Diabetes Mellitus
by: Mantas Malinauskas, et al.
Published: (2025-03-01)

Elimination of hepatocyte‐derived DPP4 downregulates cardiac immune‐ and collagen‐related genes but does not alter cardiac function in aged male mice
by: Natasha A. Trzaskalski, et al.
Published: (2025-08-01)

Assessment of the effectiveness and safety of fixed-dose combination of alogliptin and pioglitazone in real clinical practice: results of the PROsperity study
by: M. V. Shestakova, et al.
Published: (2025-05-01)

Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects
by: Dandan Zhang, et al.
Published: (2025-08-01)

Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
by: Gail Mkele
Published: (2013-12-01)

FEATURES ENZYMATIC RELEASE BIOCOMPATIBLE MICROCAPSULES WITH BUILT-IN SHELL INHIBITOR PEPTIDASE
by: E. V. Popova, et al.
Published: (2019-01-01)

Development and Validation of a Highly Sensitive LC–MS/MS Method for the Precise Quantification of Sitagliptin in Human Plasma and Its Application to Pharmacokinetic Study
by: Yuna Song, et al.
Published: (2025-07-01)

Deciphering new biomolecules, antioxidants, and human dipeptidyl Peptidase-4 inhibitor potential of green celery: Bioprospecting insights from molecular docking and in vitro investigation
by: Fan Maitri Aldian, et al.
Published: (2025-10-01)

Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study
by: Ji Yun Lee, et al.
Published: (2025-07-01)

Serum FGF23 and DPP4 Levels as Biomarkers for Coronary Artery Disease Severity in Type 2 Diabetic Patients with Coronary Heart Disease
by: Zhong X, et al.
Published: (2025-03-01)

Ketoacidosis as unexpected adverse reaction SGLT<sub>2</sub> inhibitor
by: T. M. Bukatina, et al.
Published: (2018-02-01)

Progress in studies on renal effects and molecular mechanism of SGLT-2 inhibitors
by: XING Bei, et al.
Published: (2020-01-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01)

Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study
by: Arif Albulushi, et al.
Published: (2025-07-01)

Protein hydrolysate as a source of bioactive peptides in diabetic food products
by: O. V. Zinina, et al.
Published: (2024-01-01)

Profiling of proteases involved in SARS-CoV-2 pathogenesis in human saliva: Influence of age and gender
by: Mentalla Motaz Abdellatif, et al.
Published: (2025-09-01)

Development of an Efficient Process for a Key Synthetic Intermediate of the SGLT2 Inhibitor LH-1801
by: Jun Qu, et al.

SGLT2 Inhibitors and genital infections: a prospective observational study in a tertiary care hospital
by: Numan Malik, et al.
Published: (2025-07-01)

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
by: Abhishek Kansara, et al.
Published: (2022-09-01)

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
by: Vladimir V Salukhov, et al.
Published: (2021-01-01)

Effects of RAS and SGLT2 inhibitors alone or in combination on end-stage kidney disease and/or all-cause death in patients with both diabetes and hypertension: a nationwide cohort study
by: Sangmo Hong, et al.
Published: (2025-07-01)

Early initiation of SGLT2 inhibitors in acute myocardial infarction and cardiovascular outcomes, an updated systematic review and meta-analysis
by: Davood Semirani-Nezhad, et al.
Published: (2025-07-01)

Effect of SGLT2 inhibitors on thiazolidinedione-induced changes in the volume status of patients with type 2 diabetes mellitus: a 6-month follow-up prospective study
by: Yagmur Busra Unlusoy, et al.
Published: (2025-08-01)

Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study
by: Abdullahi Ahmed Mohamed, et al.
Published: (2025-08-01)

Early hemodynamic impact of SGLT2 inhibitors in overweight cardiometabolic heart failure: beyond fluid offloading to vascular adaptation– a preliminary report
by: Nadia Salerno, et al.
Published: (2025-03-01)

Factors influencing early renal function changes after SGLT2 inhibitors use and its long-term prognosis: a real-world retrospective study
by: Bing Xie, et al.
Published: (2025-12-01)

STUDI IN SILICO POTENSI SENYAWA ALLIIN BAWANG PUTIH (Allium sativum) SEBAGAI INHIBITOR DPP-4 PADA DIABETES MELLITUS
by: Martina Kurnia Rohmah
Published: (2018-03-01)

Dypeptydylpeptidase IV Activity Ingibition after Oral Administration to Rabbits of <i>Strongylocentrotus Droebahiensis</i> Gonads Extract as Possible Biomarker of Pharmakokinetics
by: V. M. Kosman, et al.
Published: (2020-08-01)

Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study
by: Jeong-Hoon Lim, et al.
Published: (2024-08-01)

Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitors
by: Sebastian Hüper, et al.
Published: (2025-07-01)

Early Introduction of SGLT-2 Inhibitors to Improve Chronic Kidney Disease Care in People with or without Diabetes—Consensus by Indian Nephrologists
by: Manisha Sahay, et al.
Published: (2025-04-01)

3-(3-Azabicyclo[2, 2, 1]heptan-2-yl)-1,2,4-oxadiazoles as Novel Potent DPP-4 Inhibitors to Treat T2DM
by: Tatiana V. Zinevich, et al.
Published: (2025-04-01)

Impact of SGLT2 inhibitors on survival in gastrointestinal cancer patients undergoing chemotherapy and/or radiotherapy: a real-world data retrospective cohort study
by: Lucas E. Flausino, et al.
Published: (2025-03-01)

A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-07-01)

Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists – a comprehensive review
by: David Aristizábal-Colorado, et al.
Published: (2025-08-01)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01)

Evidence-based prescription for cyclo-oxygenase-2 inhibitors in sports injuries
by: D.C. Janse van Rensburg, et al.
Published: (2015-03-01)

Effect of Sodium-Glucose Cotransporter Type 2 Inhibitors on The Development and Course of Atrial Fibrillation
by: D. A. Ishmaev, et al.
Published: (2025-01-01)